Literature DB >> 25840541

GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.

Marcus C Tan1, Olca Basturk2, A Rose Brannon2, Umesh Bhanot2, Sasinya N Scott2, Nancy Bouvier2, Jennifer LaFemina1, William R Jarnagin1, Michael F Berger2, David Klimstra2, Peter J Allen1.   

Abstract

BACKGROUND: Intraductal papillary mucinous neoplasms (IPMN) are being increasingly recognized as important precursors to pancreatic adenocarcinoma. Elucidation of the genetic changes underlying IPMN carcinogenesis may improve the diagnosis and management of IPMN. We sought to determine whether different histologic subtypes of IPMN would exhibit different frequencies of specific genetic mutations. STUDY
DESIGN: Patients with resected IPMN-associated invasive carcinoma (IPMN-INV) between 1997 and 2012 were reviewed. Areas of carcinoma, high-grade dysplasia, and low-grade dysplasia were micro-dissected from each pathologic specimen. Targeted, massively parallel sequencing was then performed on a panel of 275 genes (including KRAS, GNAS, and RNF43).
RESULTS: Thirty-eight patients with resected IPMN-INV and sufficient tissue for micro-dissection were identified. Median follow-up was 2.6 years. Mutations in GNAS were more prevalent in colloid-type IPMN-INV than tubular-type IPMN-INV (89% vs 32% respectively; p = 0.0003). Conversely, KRAS mutations were more prevalent in tubular-type than colloid-type IPMN-INV (89% vs 52%, respectively; p = 0.01). For noninvasive IPMN subtypes, GNAS mutations were more prevalent in intestinal (74%) compared with pancreatobiliary (31%) and gastric (50%) subtypes (p = 0.02). The presence of these mutations did not vary according to the degree of dysplasia (GNAS: invasive 61%, high-grade 59%, low-grade 53%; KRAS: invasive 71%, high-grade 62%, low-grade 74%), suggesting that mutations in these genes occur early in IPMN carcinogenesis.
CONCLUSIONS: Colloid carcinoma associated with IPMN and its intestinal-type preinvasive precursor are associated with high frequencies of GNAS mutations. The mutation profile of tubular carcinoma resembles that of conventional pancreatic adenocarcinoma. Preoperative determination of mutational status may assist with clinical treatment decisions.
Copyright © 2015 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25840541      PMCID: PMC4409519          DOI: 10.1016/j.jamcollsurg.2014.11.029

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  28 in total

1.  Histologic, immunohistochemical, and molecular classification of 52 IPMNs of the pancreas.

Authors:  Barbara Chadwick; Carlynn Willmore-Payne; Sheryl Tripp; Lester J Layfield; Sharon Hirschowitz; Joseph Holden
Journal:  Appl Immunohistochem Mol Morphol       Date:  2009-01

2.  Activating mutations of Gsalpha in kidney cancer.

Authors:  Nicolas Kalfa; Serge Lumbroso; Nathalie Boulle; Jacques Guiter; Laurent Soustelle; Pierre Costa; Heliette Chapuis; Pierre Baldet; Charles Sultan
Journal:  J Urol       Date:  2006-09       Impact factor: 7.450

3.  Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study.

Authors:  Toru Furukawa; Günter Klöppel; N Volkan Adsay; Jorge Albores-Saavedra; Noriyoshi Fukushima; Akira Horii; Ralph H Hruban; Yo Kato; David S Klimstra; Daniel S Longnecker; Jutta Lüttges; G Johan A Offerhaus; Michio Shimizu; Makoto Sunamura; Arief Suriawinata; Kyoichi Takaori; Suguru Yonezawa
Journal:  Virchows Arch       Date:  2005-08-09       Impact factor: 4.064

Review 4.  Precursors to pancreatic cancer.

Authors:  Ralph H Hruban; Anirban Maitra; Scott E Kern; Michael Goggins
Journal:  Gastroenterol Clin North Am       Date:  2007-12       Impact factor: 3.806

5.  Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs alpha mutations.

Authors:  Michael T Collins; Nicholas J Sarlis; Maria J Merino; Jason Monroe; Susan E Crawford; Jonathan A Krakoff; Lori C Guthrie; Sandra Bonat; Pamela G Robey; Andrew Shenker
Journal:  J Clin Endocrinol Metab       Date:  2003-09       Impact factor: 5.958

6.  Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome.

Authors:  Michael D'Angelica; Murray F Brennan; Arief A Suriawinata; David Klimstra; Kevin C Conlon
Journal:  Ann Surg       Date:  2004-03       Impact factor: 12.969

7.  Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission.

Authors:  Pamela U Freda; Wendy K Chung; Naoki Matsuoka; Jane E Walsh; M Nabi Kanibir; George Kleinman; Yuanjia Wang; Jeffrey N Bruce; Kalmon D Post
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

8.  Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an "intestinal" pathway of carcinogenesis in the pancreas.

Authors:  N Volkan Adsay; Kambiz Merati; Olca Basturk; Christine Iacobuzio-Donahue; Edi Levi; Jeanette D Cheng; Fazlul H Sarkar; Ralph H Hruban; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2004-07       Impact factor: 6.394

9.  Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.

Authors:  Taylor A Sohn; Charles J Yeo; John L Cameron; Ralph H Hruban; Noriyoshi Fukushima; Kurtis A Campbell; Keith D Lillemoe
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969

10.  Integrative genomics viewer.

Authors:  James T Robinson; Helga Thorvaldsdóttir; Wendy Winckler; Mitchell Guttman; Eric S Lander; Gad Getz; Jill P Mesirov
Journal:  Nat Biotechnol       Date:  2011-01       Impact factor: 54.908

View more
  49 in total

1.  Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma.

Authors:  Olca Basturk; Michael F Berger; Hiroshi Yamaguchi; Volkan Adsay; Gokce Askan; Umesh K Bhanot; Ahmet Zehir; Fatima Carneiro; Seung-Mo Hong; Giuseppe Zamboni; Esra Dikoglu; Vaidehi Jobanputra; Kazimierz O Wrzeszczynski; Serdar Balci; Peter Allen; Naoki Ikari; Shoko Takeuchi; Hiroyuki Akagawa; Atsushi Kanno; Tooru Shimosegawa; Takanori Morikawa; Fuyuhiko Motoi; Michiaki Unno; Ryota Higuchi; Masakazu Yamamoto; Kyoko Shimizu; Toru Furukawa; David S Klimstra
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas.

Authors:  Lauren L Ritterhouse; Marina Vivero; Mari Mino-Kenudson; Lynette M Sholl; A John Iafrate; Valentina Nardi; Fei Dong
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

3.  Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas.

Authors:  Antonio Pea; Jun Yu; Neda Rezaee; Claudio Luchini; Jin He; Marco Dal Molin; James F Griffin; Helen Fedor; Shahriar Fesharakizadeh; Roberto Salvia; Matthew J Weiss; Claudio Bassi; John L Cameron; Lei Zheng; Aldo Scarpa; Ralph H Hruban; Anne Marie Lennon; Michael Goggins; Christopher L Wolfgang; Laura D Wood
Journal:  Ann Surg       Date:  2017-07       Impact factor: 12.969

4.  Intraductal Papillary Mucinous Neoplasms Arise From Multiple Independent Clones, Each With Distinct Mutations.

Authors:  Catherine G Fischer; Violeta Beleva Guthrie; Alicia M Braxton; Lily Zheng; Pei Wang; Qianqian Song; James F Griffin; Peter E Chianchiano; Waki Hosoda; Noushin Niknafs; Simeon Springer; Marco Dal Molin; David Masica; Robert B Scharpf; Elizabeth D Thompson; Jin He; Christopher L Wolfgang; Ralph H Hruban; Nicholas J Roberts; Anne Marie Lennon; Yuchen Jiao; Rachel Karchin; Laura D Wood
Journal:  Gastroenterology       Date:  2019-06-05       Impact factor: 22.682

Review 5.  The diagnosis and management of intraductal papillary mucinous neoplasms of the pancreas: has progress been made?

Authors:  Jenny Lim; Peter J Allen
Journal:  Updates Surg       Date:  2019-06-07

Review 6.  Insights into the Pathogenesis of Pancreatic Cystic Neoplasms.

Authors:  Vrishketan Sethi; Bhuwan Giri; Ashok Saluja; Vikas Dudeja
Journal:  Dig Dis Sci       Date:  2017-05-12       Impact factor: 3.199

Review 7.  Intraductal Papillary Mucinous Neoplasms of the Pancreas: Current Understanding and Future Directions for Stratification of Malignancy Risk.

Authors:  Annabelle L Fonseca; Kimberly Kirkwood; Michael P Kim; Anirban Maitra; Eugene J Koay
Journal:  Pancreas       Date:  2018-03       Impact factor: 3.327

8.  Preoperative risk prediction for intraductal papillary mucinous neoplasms by quantitative CT image analysis.

Authors:  Marc A Attiyeh; Jayasree Chakraborty; Lior Gazit; Liana Langdon-Embry; Mithat Gonen; Vinod P Balachandran; Michael I D'Angelica; Ronald P DeMatteo; William R Jarnagin; T Peter Kingham; Peter J Allen; Richard K Do; Amber L Simpson
Journal:  HPB (Oxford)       Date:  2018-08-07       Impact factor: 3.647

Review 9.  Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Kiara A Tulla; Ajay V Maker
Journal:  Langenbecks Arch Surg       Date:  2017-12-07       Impact factor: 3.445

10.  Glycomic Profiling Highlights Increased Fucosylation in Pseudomyxoma Peritonei.

Authors:  Lilli Saarinen; Pirjo Nummela; Hannele Leinonen; Annamari Heiskanen; Alexandra Thiel; Caj Haglund; Anna Lepistö; Tero Satomaa; Sampsa Hautaniemi; Ari Ristimäki
Journal:  Mol Cell Proteomics       Date:  2018-08-02       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.